Advent Pharma Ltd. Share Price

Equities

ADVENT

BD0492ADVPL9

Pharmaceuticals

End-of-day quote Dhaka S.E. 23:00:00 22/06/2024 BST 5-day change 1st Jan Change
25.4 BDT -2.68% Intraday chart for Advent Pharma Ltd. 0.00% +2.01%

Financials

Sales 2022 530M 4.51M 357M Sales 2023 558M 4.75M 375M Capitalization 2.46B 20.93M 1.65B
Net income 2022 97M 826K 65.19M Net income 2023 98M 834K 65.87M EV / Sales 2022 4.52 x
Net Debt 2022 59.61M 507K 40.06M Net Debt 2023 70.52M 600K 47.4M EV / Sales 2023 4.53 x
P/E ratio 2022
24 x
P/E ratio 2023
24.9 x
Employees 317
Yield 2022
0.8%
Yield 2023
0.76%
Free-Float 69.98%
More Fundamentals * Assessed data
Dynamic Chart
Advent Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Advent Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Advent Pharma Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Advent Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Advent Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Advent Pharma Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Advent Pharma Ltd. Completes Signing Agreement of Distributorship with Alltech Biotechnology Pvt Ltd CI
Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022 CI
Advent Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Advent Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Advent Pharma Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2021 CI
Advent Pharma Ltd. Appoints Asif Iqbal Chowdhury as Chairman CI
21,567,500 Ordinary Shares of Advent Pharma Limited are subject to a Lock-Up Agreement Ending on 12-APR-2021. CI
More news
1 day-2.68%
Current month-4.51%
1 month-5.93%
3 months-9.61%
6 months+9.48%
Current year+2.01%
More quotes
1 week
25.10
Extreme 25.1
26.40
1 month
24.90
Extreme 24.9
28.10
Current year
22.10
Extreme 22.1
35.60
1 year
22.10
Extreme 22.1
35.60
3 years
22.00
Extreme 22
37.35
5 years
16.84
Extreme 16.8449
37.35
10 years
16.84
Extreme 16.8449
41.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 38 -
Director of Finance/CFO - 23/05/15
Director/Board Member 63 30/06/17
Members of the board TitleAgeSince
Director/Board Member 63 30/06/17
Director/Board Member 65 -
Chief Executive Officer 38 -
More insiders
Date Price Change Volume
23/06/24 25.4 -2.68% 1,256,882
20/06/24 26.1 +1.16% 805,371

End-of-day quote Dhaka S.E., June 22, 2024

More quotes
Advent Pharma Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. Its product category includes aquaculture, cattle, and poultry. Its aquaculture products include GRO-PLUS, Oxi-D Bolus, and RUMIGEST HP. Its cattle products include ABC Solution, ACIPURE PLUS, AD-HISTA Vet Injection, ADBOVI Powder, ADCAL-P, ADCET BOLUS, ADCIPCIN, ADCIPCINE BOLUS, ADLYTE, ADPROLIM PLUS POWDER and ADRIZOL Bolus. Its poultry products include ADSULPH Bolus, ADVIT B COMPLEX, ADVIT C, ADVIT CP, ADVIT CP PLUS Bolus, ADVIT DB Powder, ADVIT E-SEL, ADVIT-D PLUS Solution, ADVOMICA, ADZURIL, ADZYL Bolus, ADZYME LIQUID, ADZYME POWDER, COUGH OFF, EGG BOOST, FERON VET, Liver On, MASTIVIT, NEO SUPER VET, NEPHROSOL, TOXOSORB, TILFOS VET, NUTARIN, and others.
More about the company
  1. Stock Market
  2. Equities
  3. ADVENT Stock